Haunts the efforts of all biomedical researchers in ME CFS, and it is particularly acute in these gene biomarker studies which will require million of dollars to come to a definitive conclusion. As Ale x Fergusson MSP said in the Parliamentary members' business debate in June 2005 motion S2M2852 ; on the subject of a cure for myalgic encephalomyelitis, it is entirely unacceptable that major funding bodies seem uninterested in novel gene research particularly when large traunches of money have been allocated to research on non-curative psychosocial strategies designed to 'manage' symptoms. Illnesses are most easily accepted when they have a specific clinical or scientific 'signature'-- a biochemical test, a cluster of specific symptoms or signs, etc.--that confers legitimacy in the eyes of healthcare professionals. Until then, patients are in a no-man's land between the living and the well, subject to a variety of quasi-therapeutic interventions. ME CFS has been called the "disease of a thousand names", but it has also been the disease of a thousand false dawns and a thousand broken promises. Yet, the discovery of a clinical or scientific 's ignature' for ME CFS, indicative of the physical terrain, would transform this situation at a single sharp stroke. In the longer term, work using genome-wide scanning technologies has the potential to reveal such a 's ignature': to quote Steinau et al. 2004 ; , "Biomarkers characteristic of CFS could contribute to precision in case ascertainment, identify heterogeneity in the CFS population to clarify contributing pathways to disease, suggest novel therapeutic targets, and provide indicators of disease progression and prognosis, because reversing coumadin.
We are subject to price control restrictions on our pharmaceutical products in the majority of countries in which we operate. There is a risk that other jurisdictions may enact price control restrictions, and that the restrictions that currently exist may be increased. Our future sales and gross prot could be materially aected if we are unable to obtain appropriate price increases. Our research and development activities involve the controlled use of potentially harmful biological materials as well as hazardous materials, chemicals and various radioactive compounds. We cannot completely eliminate the risk of accidental contamination or injury from the use, storage, handling or disposal of these materials. In the event of contamination or injury, we could be held liable for damages that result. Any liability could exceed our resources. We are subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of these materials and specied waste products. The cost of compliance with, or any potential violation of, these laws and regulations could be signicant. Any insurance we maintain may not be adequate to cover our losses. Our stockholder rights plan and anti-takeover provisions of our charter documents could provide our board of directors with the ability to delay or prevent a change in control of us. Our stockholder rights plan, provisions of our certicate of incorporation and provisions of the Delaware General Corporation Law could provide our board of directors with the ability to deter hostile takeovers or delay, deter or prevent a change in control of us, including transactions in which stockholders might otherwise receive a premium for their shares over then current market prices. We may issue additional equity securities and thereby materially and adversely aect the price of our common stock. We are authorized to issue, without stockholder approval, 10, 000, 000 shares of preferred stock, none of which were outstanding as of December 31, 2003, in one or more series. Any such series of preferred stock could contain dividend rights, conversion rights, voting rights, terms of redemption, redemption prices, liquidation preferences or other rights superior to the rights of holders of our common stock. Our board of directors has no present intention of issuing any such preferred stock, but reserves the right to do so the future. In addition, we are authorized to issue up to 200 million shares of our common stock without stockholder approval. We are also authorized to issue, without stockholder approval, securities convertible into either shares of common stock or preferred stock. If we issue additional equity securities, the price of our securities may be materially and adversely aected. A number of internal and external factors have caused and may continue to cause the market price of our stock to be volatile. The market prices for securities of companies engaged in pharmaceutical development, including us, have been volatile. Many factors, including many over which we have no control, may have a signicant impact on the market price of our common stock, including without limitation: , our competitors' announcement of technological innovations or new commercial products; , changes in governmental regulation; , our competitors' receipt of regulatory approvals; , our competitors' developments relating to patents or proprietary rights; 41.

Respondent shall be able to consume legend drugs or controlled substances prescribed by the Respondent's primary physician, Tina Burns, MD, except in the case of an emergency or upon a proper referral from the Respondent's primary physician. The Respondent shall immediately notify the Board office in writing of the name of the Respondent's primary physician each time the Respondent changes primary physicians.